Sign in
Not yet recruitingEarly phase 1

QH101 cell therapy for cancer that has spread to the brain or spine

Tests different doses of QH101 cells in adults with brain, meningeal or spinal cord metastases.

Key facts

Who runs it
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors
Status
Not yet recruiting
Phase
Early phase 1
People taking part
7 people, planned
Started
31 May 2026
Expected to end
31 May 2027
Type of study
Interventional
Treatments tested
  • QH101 Cell Injection
Record updated
18 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid cancer that has spread to the brain, the brain or spinal cord linings (meninges), or the spinal cord. Standard treatment must have failed, or there must be no standard option. Everyone gets QH101, a donor cell therapy given into the spinal fluid.

Age
18 years or older
Sex
All sexes
Disease stage
Spread (metastases) to the brain, meninges or spinal cord, confirmed by tissue tests. Brain lesions cannot be removed by surgery, or meningeal or spinal cord lesions cannot be operated on. Brain lesions grew after standard radiotherapy (WBRT/SRS) and repeat radiotherapy is not possible. At least one measurable lesion on contrast MRI, unless only the meninges are affected. Able to carry out daily activities (ECOG ≤2 or KPS ≥60). Expected to live at least 8 weeks.
Earlier treatment
Standard therapy must have failed or not exist. No radiation to the brain or spinal cord within 7 days before the first QH101 dose. No earlier CAR-T or other cell immunotherapy.
Biomarker or test result
Blood tests before the first dose: WBC ≥ 3 × 10⁹/L, lymphocytes ≥ 0.8 × 10⁹/L, Hb ≥ 90 g/L, platelets ≥ 90 × 10⁹/L, ALT and AST < 1.5×ULN, creatinine < 1.5×ULN, total bilirubin < 1.5×ULN, PT and APTT ≤ 1.25×ULN. Negative pregnancy test for women who can become pregnant.

Main reasons for not taking part

  • Blood cancers such as lymphoma or leukemia that spread to the brain or spinal cord
  • Spread to the brainstem or upper neck spinal cord (C1/2)
  • Strong pressure inside the skull or large swelling from brain lesions
  • Epilepsy that medicine does not control well
  • Active infections, immune deficiency, serious heart problems, or being unable to have an MRI

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Age ≥18 years
  • ECOG ≤2 or KPS ≥60
  • Life expectancy ≥8 weeks as assessed by the investigator
  • Pathologically and/or histologically confirmed malignant tumors with brain, meningeal, and spinal cord metastases that have failed standard therapy or lack standard treatment options may be considered for enrollment
  • Intracranial metastases must meet the following characteristics:; Unresectable by craniotomy for solitary/focal (≤3 lesions)/multiple (>3 lesions) intracranial metastases; or inoperable leptomeningeal or spinal cord metastases; Inclusion Criteria Intracranial lesions that progressed after standard treatment, including whole-brain radiotherapy/stereotactic radiosurgery (WBRT/SRS), and are not suitable for repeat radiotherapy
  • For brain/spinal cord parenchymal metastases, contrast-enhanced MRI must show at least one measurable lesion (according to iRANO criteria); for patients with meningeal lesions only, those deemed likely to benefit from this study by investigator judgment may also be considered for inclusion (efficacy assessed using RANO-LM criteria)
  • Basic normal bone marrow reserve function and normal hepatic and renal function (laboratory tests must meet the following criteria prior to first QH101 administration):; White blood cell count (WBC) ≥ 3 × 10⁹/L; Lymphocyte count (LY) ≥ 0.8 × 10⁹/L; Hemoglobin (Hb) ≥ 90 g/L; Platelet count (PLT) ≥ 90 × 10⁹/L; Alanine aminotransferase (ALT) \& aspartate aminotransferase (AST) < 1.5×ULN; Serum creatinine (Cr) < 1.5×ULN; Total bilirubin < 1.5×ULN; PT \& APTT ≤ 1.25×ULN
  • Pregnancy test must be negative for women of childbearing potential; both male and female subjects must agree to use effective contraception during treatment and for 1 year thereafter
  • Ability to understand trial requirements and procedures, and willingness to participate in the clinical study as required
  • Signing of the trial informed consent form

Who cannot take part

  • Received central nervous system-directed radiation within 7 days prior to the first infusion of QH101
  • Currently receiving any other investigational treatments
  • Previously received CAR-T or other cellular immunotherapies
  • Patients with hematologic malignancies (such as lymphoma, leukemia, etc.) with central nervous system metastases
  • Patients with primary or secondary epilepsy/epileptic syndrome that is difficult to control with medication
  • Uncontrolled comorbidities, including but not limited to: ongoing or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or psychiatric/social conditions limiting patient compliance with study requirements
  • Known psychiatric disorders or substance abuse disorders that may affect compliance with trial requirements
  • Patients with active infections requiring systemic treatment
  • Severe cardiovascular damage: history of New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction or stroke within 6 months after first dosing, or clinically significant arrhythmias requiring treatment at screening
  • Allergic to immunotherapy or related cellular therapies
  • Patients with metastases in the brainstem and high cervical spinal cord, including midbrain, pons, medulla oblongata, and C1/2 segments of the cervical spinal cord
  • Patients with significant mass effect from intracranial lesions and signs of increased intracranial pressure (such as severe headache, projectile vomiting, papilledema, altered consciousness, or imaging showing significant edema, midline shift ≥1 cm, compression of peribrain cisterns such as suprasellar cistern, quadrigeminal cistern, interpeduncular cistern, or ambient cistern)
  • Diagnosed with an immunodeficiency
  • Inability to undergo magnetic resonance imaging (MRI)
  • Other reasons that the investigator considers make the patient unsuitable for participation in this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

QH101 is an allogeneic TCR-enhanced Vδ2 T cell therapy product engineered to express BTN protein-specific binding elements on the cell surface. This innovative approach harnesses the natural cytotoxic capabilities of Vδ2 T cells while augmenting their ability to recognize BTN proteins, thereby significantly improving tumor cell elimination efficiency. Notably, QH101 is designed without co-stimulatory signal domains or the CD3ζ domain, which prevents T cell exhaustion from overactivation and effectively enhances in vivo persistence.

The group in the trial

  • Patients with metastatic malignant solid tumors to the brain, meninges, and spinal cordTreatment being tested

    Patients with malignant solid tumors metastasizing to the brain, meninges, or spinal cord receive QH101 cell injection solution via intrathecal injection or Ommaia reservoir infusion.

    Treatment: QH101 Cell Injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploratory Clinical Study of Dose Escalation for QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors Three Dose Groups Are Established: 1×10⁷ enTCR Vδ2T Cells Per Infusion (Low Dose), 3×10⁷ enTCR Vδ2T Cells Per Infusion (Medium Dose), and 6×10⁷ enTCR Vδ2T Cells Per Infusion (High Dose). The Dose Escalation Rules Are as Follows: The First Enrolled Subject Receives Low-dose Cell Infusion. If no Dose-limiting Toxicity (DLT) Events Occur After Infusion, the Second Enrolled Subject Receives Medium-dose Infusion; the Medium and Hig
Plain-language title
QH101 cell therapy for cancer that has spread to the brain or spineGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
18 June 2026